Central Nervous SystemOncologyBiotechnologyMedicalTherapeutics
Description
Puma Biotechnology, Inc. operates as a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients.
The company is currently commercializing NERLYNX, an oral versi…
Analysis
Quality compounder
Puma Biotechnology, Inc. is a quality compounder: a well-run business trading at a price that reflects what it is worth. One caution: reported profits have recently run ahead of actual cash, which we track closely.
The price is attractive. You pay 10.7× its owner earnings: the cash an owner could take out each year, which is in the historically attractive zone.
The trajectory is moderate and the balance sheet is adequate. The company scores 10/20 on our value-creation score: creating some value. Analyst sentiment is cautious.
What to watch: Reported profits have run ahead of actual cash for several periods. As always: this describes the company's numbers; it is not a recommendation.
360° rank · history
1007550250
Mar 202654
33
2026
All-time high
54
Mar 2026
All-time low
33
Jun 2026
Average rank
44
across all years
Detailed & Historical Ranks
Deep dive into 15 detailed ranks and 3 years of history.
Current202520242023
Price/Sales
79
—
—
—
Price/Earnings
22
—
—
—
Price/Book
48
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
40
—
—
—
Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.